Skip to Main Content

Advertisement

Skip Nav Destination

Abstract OT3-03-02: A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)

Cancer Res (2019) 79 (4_Supplement): OT3-03-02.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Laura Cortesi
  • Hope S. Rugo
  • Christian Jackisch
Targeted Oncology (2021) 16 (3): 255.
  • Jin Sun Lee
  • Susan E. Yost
  • Yuan Yuan
Cancers (2020) 12 (6): 1404.
Close Modal

or Create an Account

Close Modal
Close Modal